查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722815

2025 年至 2033 年抗高血脂藥物市場規模、佔有率、趨勢及預測（依藥物類別、給藥途徑、配銷通路及地區分類）

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2024年全球抗高血脂藥物市場規模價值131億美元。展望未來， IMARC Group估計到2033年市場規模將達到186億美元，2025-2033年期間的複合年成長率為3.9%。北美目前佔據市場主導地位，到 2024 年將佔據超過 32.7% 的顯著市場。高血脂症和心血管疾病的高發性、人口老化、肥胖、久坐的生活方式和不健康的飲食習慣推動了北美市場的發展。強大的研發投入、先進的醫療保健基礎設施、政府舉措、他汀類藥物、PCSK9 抑制劑和新型降血脂藥物的採用率不斷提高，以及保險覆蓋，進一步推動了抗高脂血症藥物的市場佔有率。

抗高血脂藥物有助於降低血清膽固醇和血液中的各種脂質的水平。它們可以與不同的藥物一起服用，以控制高膽固醇並降低某些疾病的風險。目前，世界各地都有不同的類別，可以根據患者的膽固醇狀況、潛在疾病和其他因素進行給藥。一些常見的抗高血脂藥物包括他汀類藥物、抗高血脂組合、膽汁酸螯合劑、膽固醇吸收抑制劑、纖維酸衍生物和 PCSK9 抑制劑。

抗高血脂藥物市場趨勢：

久坐的生活方式、尼古丁成癮和大量食用高脂肪食物導致高脂血症盛行率不斷上升，這是催化抗高血脂藥物需求的關鍵因素之一。此外，高血脂症會增加冠狀動脈疾病（CAD）的風險，而冠狀動脈疾病是全世界成年人最常見的死亡原因。因此，對這些藥物的需求不斷增加，以降低高密度脂蛋白（LDL）膽固醇和三酸甘油酯的過高水平，同時提高高密度脂蛋白（HDL）膽固醇的過低水平。除此之外，它們也用於治療高膽固醇和各種脂質疾病的兒童。此外，兒科族群中遺傳性和後天性脂質和脂蛋白代謝紊亂數量的激增，對抗高脂血症藥物的需求產生了積極影響，以降低住院率和過早死亡率。此外，新型先進藥物的批准也為市場創造了良好的前景。除此之外，世界各地的藥物化學家正在設計、合成和評估這些藥物的各種新分子，預計這將有助於市場的成長。

本報告回答的關鍵問題

  • 降血脂藥市場有多大？降血脂藥物市場未來前景如何？
  • 推動抗高血脂藥物市場的關鍵因素有哪些？
  • 哪個地區佔據抗高血脂藥物最大的市佔率？
  • 全球抗高血脂藥物市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球抗高血脂藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥品類別

  • 他汀類藥物
  • 膽汁酸螯合劑
  • 膽固醇吸收抑制劑
  • 纖維酸衍生物
  • PCSK9抑制劑
  • 組合
  • 其他

第7章：市場區隔：依行政途徑

  • 口服
  • 靜脈

第8章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售店
  • 線上零售商

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A5622

The global antihyperlipidemic drugs market size was valued at USD 13.1 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.6 Billion by 2033, exhibiting a CAGR of 3.9% during 2025-2033. North America currently dominates the market, holding a significant market share of over 32.7% in 2024. The market in North America is fueled by the high prevalence of hyperlipidemia and cardiovascular diseases, aging populations, obesity, sedentary lifestyles, and unhealthy diets. Strong R&D investments, advanced healthcare infrastructure, government initiatives, rising adoption of statins, PCSK9 inhibitors, and novel lipid-lowering drugs, along with insurance coverage, further fuel antihyperlipidemic drugs market share.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

Breakup by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1.How big is the antihyperlipidemic drugs market?
  • 2.What is the future outlook of the antihyperlipidemic drugs market?
  • 3.What are the key factors driving the antihyperlipidemic drugs market?
  • 4.Which region accounts for the largest antihyperlipidemic drugs market share?
  • 5.Which are the leading companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2024
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players